PYC THERAPEUTICS LIMITED (PYC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PYC

PYC - PYC THERAPEUTICS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.01
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.365

19 Mar
2026

-0.030

OPEN

$1.42

-2.15%

HIGH

$1.42

2,105,928

LOW

$1.34

TARGET
$2.30 68.5% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OPT . OSL . PAR . PER . PNV . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
PYC: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 9.8 - 5.3 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-9.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx28.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-51.6 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-40.23 %
Return on Invested Capital xxxxxxxxxxxxxxx-40.00 %
Return on Assets xxxxxxxxxxxxxxx-36.65 %
Return on Equity xxxxxxxxxxxxxxx-40.23 %
Return on Total Capital xxxxxxxxxxxxxxx-59.97 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-52.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx153 M
Price To Book Value xxxxxxxxxxxxxxx4.45

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx1.0 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx1 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx75 M
Research & Development xxxxxxxxxxxxxxx70 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

17/03/2026

1

Speculative Buy

$2.30

68.50%

PYC Therapeutics has provided key elements of a phase 3 trial design for its novel drug candidate, VP-001, to the US FDA, with key details aligned with FDA guidelines.

Bell Potter notes the "takeaway" for investors is the fact the randomised phase 3 trial will be long, likely four years in duration.

Assuming the trial commences in 2027, the broker forecasts US approval and launch in 2032. Importantly the alignment with the FDA is a critical element for de-risking. 

Speculative Buy. Target unchanged at $2.30.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -5.30 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -8.90 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

10/12/2025

1

Buy

$2.85

108.79%

Canaccord Genuity has transferred coverage of PYC Therapeutics to Madeleine Williams due to an analyst departure and re-allocation of resources.

No change to Buy rating and $2.85 target.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -13.60 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -18.80 cents.
Access Extra Coverage Research History >

PYC STOCK CHART

FNArena News on PYC

1
Australian Broker Call *Extra* Edition – Dec 10, 2025

Dec 10 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Nov 27, 2025

Nov 27 2025 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Sep 23, 2025

Sep 23 2025 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Sep 15, 2025

Sep 15 2025 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Sep 09, 2025

Sep 09 2025 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
2
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
3
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
4
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
5
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
6
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
7
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
8
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
9
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
10
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View